New Pfizer

Pfizer to Merge Off-Patent Drug Business With Mylan – The Wall Street Journal.

Pfizer, a global leader in pharmaceuticals, continues its restructure. Pfizer followed the trend of ridding itself of its consumer health business not that long ago. Now, it will merge it’s off-patent product portfolio with Mylan in a new entity. It also recently acquired Array Biopharma.

Advertisements